Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WXFL10030390 tablets plus toripalimab in advanced solid tumors and lymphoma
CTR20222481Phase 2Active
- Sponsor
- Shanghai Jiatan Pharmatech
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of WXFL10030390 in Nonhematologic neoplasms, lymphoma, sponsored by Shanghai Jiatan Pharmatech. Started Nov 2022; status: active.
02
Drugs
WXFL10030390
03
Conditions
Nonhematologic neoplasmslymphoma
Beyond the preview
Go deeper on CTR20222481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222481.